Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 213

Sort by

Sort Order Select

Journal Articles

Outcomes Among Adult Recipients of CAR T-cell Therapy for Burkitt Lymphoma

Blood blood.2024026831.

https://doi.org/10.1182/blood.2024026831

Published: 2025

Includes: Supplemental data

Journal Articles

Concomitant Use of Antibiotics During Immune Checkpoint Inhibitor (CPI)-Based Salvage Therapy Does Not Impact Post-ASCT Outcomes in Patients with Relapsed/Refractory Hodgkin Lymphoma (RRHL)

Blood (2024) 144 (Supplement 1): 4425.

https://doi.org/10.1182/blood-2024-197923

Published: 2024

Journal Articles

Acalabrutinib and Venetoclax (AV) Combination for 2 Years for Patients with Previously Treated CLL/SLL - the Avenue-2 Trial

Jennifer J. Huang, Laura Samples, Margie Fredericks, Stephanie Louie, Ramya Pulluru, Christine Crider, Mehrdad Shakib-Azar, Neena Kennedy, Vikram Raghunathan, Christina Poh, Mengyang Di, Stephen D. Smith, Brian G. Till, Ajay K. Gopal, Chaitra S. Ujjani, Ryan C. Lynch, Mazyar Shadman

Blood (2024) 144 (Supplement 1): 4634.2.

https://doi.org/10.1182/blood-2024-204491

Published: 2024

Journal Articles

Barriers to Investigator-Initiated Clinical Trial Enrollment in Frontline Large B-Cell Lymphoma: A Single-Center Retrospective Analysis

Carrie I Ho, Neena Kennedy, Mengyang Di, Ajay K. Gopal, Ryan C Lynch, Christina Poh, Vikram Raghunathan, Heather Rasmussen, Mazyar Shadman, Brian G. Till, Chaitra S. Ujjani, Stephen D. Smith

Blood (2024) 144 (Supplement 1): 783.

https://doi.org/10.1182/blood-2024-208269

Published: 2024

Journal Articles

Pralatrexate Is Effective in Cytotoxic Cutaneous T-Cell Lymphomas

Christina Poh, Jenna M. Voutsinas, Ivan Huang, Edus H. Warren, Caitlin A. Crimp, Mazyar Shadman, Ryan C. Lynch, Brian G. Till, Chaitra S. Ujjani, Mengyang Di, Vikram Raghunathan, Stephen D. Smith, Qian Vicky Wu, Michi M. Shinohara, Ajay K. Gopal

Blood (2024) 144 (Supplement 1): 1684.

https://doi.org/10.1182/blood-2024-194018

Published: 2024

Journal Articles

Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin (P-GVD) for Classical Hodgkin Lymphoma (CHL) in the Real-World Setting

Blood (2024) 144 (Supplement 1): 4431.

https://doi.org/10.1182/blood-2024-200719

Published: 2024

Journal Articles

Potential Delayed Immune-Related Adverse Events in Patients Treated with Frontline Pembrolizumab + AVD for Classic Hodgkin Lymphoma

Thomas M Kuczmarski, Chaitra S. Ujjani, Christina Poh, Edus H. Warren, Stephen D. Smith, Mazyar Shadman, Brian G. Till, Vikram Raghunathan, Yolanda D Tseng, Hongyan Du, Jacquelin Vandermeer, Alyssa Kelly, Heather Rasmussen, Jenna M. Voutsinas, Ajay K. Gopal, Ryan C Lynch

Blood (2024) 144 (Supplement 1): 1667.

https://doi.org/10.1182/blood-2024-208412

Published: 2024

Journal Articles

Low Rates of Febrile Neutropenia Despite Frequent Grade 4 Neutropenia in Patients Treated with Pembrolizumab + AVD in Untreated Classic Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 1666.

https://doi.org/10.1182/blood-2024-206601

Published: 2024

Journal Articles

Real-World Blood Counts in Patients Treated with Venetoclax for Relapsed or Refractory CLL/SLL

Laura Samples, Sirin Khajaviyan, Sara Keshmiri, Ryan S. Basom, Ryan C Lynch, Vikram Raghunathan, Mengyang Di, Mehrdad Shakib-Azar, Christine Crider, Margie Fredericks, Christina Poh, Stephanie Louie, Stephen D. Smith, Brian G. Till, Ajay K. Gopal, Chaitra S. Ujjani, Mazyar Shadman

Blood (2024) 144 (Supplement 1): 6785.

https://doi.org/10.1182/blood-2024-211971

Published: 2024

Journal Articles

Quality of Life during Survivorship Following Autologous Stem Cell Transplant for Mantle Cell Lymphoma

Mengyang Di, Carrie I Ho, Stephen D. Smith, Mazyar Shadman, Chaitra S. Ujjani, Ryan C. Lynch, Christina Poh, Vikram Raghunathan, Brian G. Till, Edus H. Warren, Ajay K. Gopal, Stephanie J. Lee

Blood (2024) 144 (Supplement 1): 5116.

https://doi.org/10.1182/blood-2024-201827

Published: 2024

Journal Articles

Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) in Second Line Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma: 5-Year Long Term Follow up

Ryan C. Lynch, Ryan D. Cassaday, Stephen D. Smith, Andrew J. Cowan, Edus H. Warren, Mazyar Shadman, Brian G. Till, Chaitra S. Ujjani, Karolyn Morris, Heather Rasmussen, Jenna M. Voutsinas, Ajay K. Gopal

Blood (2024) 144 (Supplement 1): 3043.

https://doi.org/10.1182/blood-2024-206047

Published: 2024

Journal Articles

Trial in Progress: ST-067 (decoy-resistant IL-18) with Teclistamab in Multiple Myeloma

Rahul Banerjee, Jacquelin Vandermeer, Jeremy Barton, Michael Mangone, Beatrice P. McQueen, Jordan Gauthier, Aaron M Ring, Ajay K. Gopal, Geoffrey R. Hill, Andrew J. Cowan

Blood (2024) 144 (Supplement 1): 7100.

https://doi.org/10.1182/blood-2024-198751

Published: 2024

Journal Articles

First-in-Human Phase 1a Clinical Trial of the Investigational New Drug ST-001, a Novel Nano-Phospholipid Dispersion Formulation of Fenretinide, in Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma

Ali Moiin, Yamini Donekal, Louis Scarmoutzos, Michael Burns, Robert Patterson, Earle Holsapple, III, Ajay K. Gopal, Ralph Parchment, Oleg Akilov

Blood (2024) 144 (Supplement 1): 4453.1.

https://doi.org/10.1182/blood-2024-211734

Published: 2024

Journal Articles

A Pilot Trial of Low Dose-Mosunetuzumab for Low-Tumor Burden Indolent B-Cell Lymphoma: Trial in Progress

Carrie I Ho, Mengyang Di, Ryan C Lynch, Christina Poh, Vikram Raghunathan, Mazyar Shadman, Stephen D. Smith, Brian G. Till, Paul S Martin, Chaitra S. Ujjani, Ajay K. Gopal

Blood (2024) 144 (Supplement 1): 1661.2.

https://doi.org/10.1182/blood-2024-204154

Published: 2024

Journal Articles

Autoimmune Outcomes in Patients with Concurrent Autoimmune Disease Receiving CD19 CAR T-Cell Therapy for Lymphoma

Jennifer J. Huang, Namrata Singh, Mazyar Shadman, Ryan S. Basom, Andrea Kalus, Andrew J Portuguese, Emily C Liang, Natalie Wuliji, Alexandre V. Vinaud Hirayama, Aude G Chapuis, Folashade Otegbeye, Filippo Milano, Ryan D. Cassaday, Ajay K. Gopal, Brian G. Till, Edus H. Warren, Jordan Gauthier, Lawrence Fong, David G. Maloney

Blood (2024) 144 (Supplement 1): 7132.

https://doi.org/10.1182/blood-2024-201809

Published: 2024

Journal Articles

Analyzing Rates of Exclusion Among Patients Living with HIV in U.S.-Based Non-Hodgkin Lymphoma Clinical Trials from 2014-2024

Daniel J. Olivieri, Ajay K. Gopal, Manoj P. Menon

Blood (2024) 144 (Supplement 1): 5041.

https://doi.org/10.1182/blood-2024-208921

Published: 2024

Journal Articles

High Rates of Undetectable MRD By Phased-Seq on Interim and End of Treatment Timepoints in Untreated Advanced Stage Chl Treated with Pembrolizumab + AVD

Blood (2024) 144 (Supplement 1): 3051.

https://doi.org/10.1182/blood-2024-206512

Published: 2024

Journal Articles

Impact of Immunophenotype on Clinical Disease Characteristics and Outcomes in T-Cell Prolymphocytic Leukemia

Christina Poh, Xueyan Chen, Jenna M. Voutsinas, Edus H. Warren, Mazyar Shadman, Ryan C. Lynch, Brian G. Till, Chaitra S. Ujjani, Mengyang Di, Vikram Raghunathan, Stephen D. Smith, Qian Vicky Wu, Sindhu Cherian, Ajay K. Gopal

Blood (2024) 144 (Supplement 1): 3069.

https://doi.org/10.1182/blood-2024-205892

Published: 2024

Journal Articles

Total Body Irradiation Versus Chemotherapy-Only Conditioning in Autologous Hematopoietic Stem Cell Transplantation for Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 2224.

https://doi.org/10.1182/blood-2023-184728

Published: 2023

Journal Articles

Machine Learning-Based Time-Series Clustering Identifies Archetypal Trajectories of Hematotoxicity after CAR T-Cell Therapy

Blood (2023) 142 (Supplement 1): 2143.

https://doi.org/10.1182/blood-2023-174106

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Outcomes Among Adult Recipients of CAR T-cell Therapy for Burkitt Lymphoma

Concomitant Use of Antibiotics During Immune Checkpoint Inhibitor (CPI)-Based Salvage Therapy Does Not Impact Post-ASCT Outcomes in Patients with Relapsed/Refractory Hodgkin Lymphoma (RRHL)

Acalabrutinib and Venetoclax (AV) Combination for 2 Years for Patients with Previously Treated CLL/SLL - the Avenue-2 Trial

Barriers to Investigator-Initiated Clinical Trial Enrollment in Frontline Large B-Cell Lymphoma: A Single-Center Retrospective Analysis

Pralatrexate Is Effective in Cytotoxic Cutaneous T-Cell Lymphomas

Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin (P-GVD) for Classical Hodgkin Lymphoma (CHL) in the Real-World Setting

Potential Delayed Immune-Related Adverse Events in Patients Treated with Frontline Pembrolizumab + AVD for Classic Hodgkin Lymphoma

Low Rates of Febrile Neutropenia Despite Frequent Grade 4 Neutropenia in Patients Treated with Pembrolizumab + AVD in Untreated Classic Hodgkin Lymphoma

Real-World Blood Counts in Patients Treated with Venetoclax for Relapsed or Refractory CLL/SLL

Quality of Life during Survivorship Following Autologous Stem Cell Transplant for Mantle Cell Lymphoma

Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) in Second Line Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma: 5-Year Long Term Follow up

Trial in Progress: ST-067 (decoy-resistant IL-18) with Teclistamab in Multiple Myeloma

First-in-Human Phase 1a Clinical Trial of the Investigational New Drug ST-001, a Novel Nano-Phospholipid Dispersion Formulation of Fenretinide, in Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma

A Pilot Trial of Low Dose-Mosunetuzumab for Low-Tumor Burden Indolent B-Cell Lymphoma: Trial in Progress

Autoimmune Outcomes in Patients with Concurrent Autoimmune Disease Receiving CD19 CAR T-Cell Therapy for Lymphoma

Analyzing Rates of Exclusion Among Patients Living with HIV in U.S.-Based Non-Hodgkin Lymphoma Clinical Trials from 2014-2024

High Rates of Undetectable MRD By Phased-Seq on Interim and End of Treatment Timepoints in Untreated Advanced Stage Chl Treated with Pembrolizumab + AVD

Impact of Immunophenotype on Clinical Disease Characteristics and Outcomes in T-Cell Prolymphocytic Leukemia

Total Body Irradiation Versus Chemotherapy-Only Conditioning in Autologous Hematopoietic Stem Cell Transplantation for Large B-Cell Lymphoma

Machine Learning-Based Time-Series Clustering Identifies Archetypal Trajectories of Hematotoxicity after CAR T-Cell Therapy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only